Analyst Surprised By Exelixis Q2 Revenue Miss, Delays STELLAR-304 Readout, Halts STELLAR-305 Phase 3 Plans
1. EXEL's Q1 2025 adjusted earnings beat consensus at 75 cents per share. 2. Quarterly sales reached $568.3 million, missing the consensus of $571.27 million. 3. Cabozantinib revenues increased to $520 million, up from $437.6 million last year. 4. EXEL maintained 2025 sales guidance of $2.25-$2.35 billion, behind $2.334 billion consensus. 5. William Blair notes Cabometyx's continued strength in renal cell carcinoma.